Retinal Vein Occlusion (RVO) occurs when the vein draining blood from the retina is blocked, leading to complications such as macular edema and vision loss.

Medically reviewed by Bryan M. Wolynski, ODMedically reviewed by Bryan M. Wolynski, OD Maintaining eye health is top of mind ...

Researchers have found that psoriasis significantly increases the risk of retinal vein occlusion (RVO) in patients with Type ...

Roche, represented by Ali Abdulwahab Al Mutawa Commercial Company (AAW) in Kuwait, announced today that the European ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

OPUVIZ has been recommended for approval in adult patients for the treatment of neovascular age related macular degeneration, visual impairment due to macular oedema secondary to retinal vein ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.

The authors concluded that the switch from aflibercept biosimilar ranibizumab in patients with nAMD demonstrated efficacy in ...

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...